7/14/2008

Amgen will pay Johnson & Johnson's Ortho Biotech Products $200 million to end litigation involving three drugs that boost blood cells. Amgen was accused of violating antitrust laws when it offered discounts and incentives to oncology clinics for Aranesp, Neupogen and Neulasta. The company denies any wrongdoing.

Related Summaries